Drugs from the deep: Marine natural products as drug candidates

Drug Discovery Today

Volumn 8, Issue 12, 2003, Pages 536-544

  Haefner, Burkhard ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Bioprospecting; Drug Discovery; Drugs; Marine; Microbial; Molecular Medicine; Natural products; Pharmaceutical Science

Indexed keywords

1 O (ALPHA GALACTOPYRANOSYL) 2 HEXACOSANOYLAMINO 1,3,4 OCTADECANETRIOL; 3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 6 CHLORO 8 NICOTINAMIDO BETA CARBOLINE; AEROPLYSININ; ALPHA CONOTOXIN; ALPHAA CONOTOXIN; AM 336; ANTINEOPLASTIC AGENT; BRYOSTATIN 1; BRYOSTATIN 2; CALCIUM CHANNEL BLOCKING AGENT; CHEMICAL WARFARE AGENT; CYTARABINE; HYMENIALDISINE; IMMUNOSTIMULATING AGENT; KAPPA CONOTOXIN; LAF 389; MORPHINE; MU CONOTOXIN; MUO CONOTOXIN; NATURAL PRODUCT; NERISTATIN 1; NOSTODIONE A; OMEGA CONOTOXIN; OMEGA CONOTOXIN MVIIA; PACLITAXEL; PROTEIN KINASE C INHIBITOR; PSI CONOTOXIN; SNAIL VENOM; TRABECTEDIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; BIODIVERSITY; BIOGENESIS; BRYOZOA; CHRONIC PAIN; CLINICAL TRIAL; CONSTIPATION; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; DRUG RESEARCH; DRUG TOLERANCE; GENETIC VARIABILITY; HUMAN; INVERTEBRATE; MARINE ENVIRONMENT; MICROORGANISM; NEUROLOGIC DISEASE; NONHUMAN; PREDATOR; PREDICTION; PREY; RESPIRATORY TRACT DISEASE; REVIEW; SCHIZOPHRENIA; SHARK; SNAIL; SPONGE (PORIFERA); TREATMENT INDICATION;

ANTINEOPLASTIC AGENTS; BIOLOGICAL PRODUCTS; CLINICAL TRIALS; DNA, NEOPLASM; ENZYME INHIBITORS; HUMANS; ION CHANNELS; MARINE BIOLOGY; MICROTUBULES; PHARMACEUTICAL PREPARATIONS; PHOSPHOLIPASES A; PROTEIN-SERINE-THREONINE KINASES;

EID: 0038461995     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(03)02713-2     Document Type: Review

References (70)

1. Mayer A.M.S., Lehmann V.K.B. Marine pharmacology. The Pharmacologist. 42:2000;62-69.
2. Proksch P., et al. Drugs from the sea - current status and microbiological implications. Appl. Microbiol. Biotechnol. 59:2002;125-134.
3. Jones R.M., Bulaj G. Conotoxins - new vistas for peptide therapeutics. Curr. Pharm. Des. 6:2000;1249-1285.
4. McIntosh J.M., Jones R.M. Cone venom - from accidental stings to deliberate injection. Toxicon. 39:2001;1447-1451.
5. Jain K.K. An evaluation of intrathecal Ziconotide for the treatment of chronic pain. Expert Opin. Investig. Drugs. 9:2000;2403-2410.
6. Hale K.J., et al. The chemistry and biology of the bryostatin antitumour macrolides. Nat. Prod. Rep. 19:2002;413-453.
7. Clamp A., Jayson G.C. The clinical development of the bryostatins. Anticancer Drugs. 13:2002;673-683.
8. Davidson S.K., et al. Evidence for the biosynthesis of bryostatins by the bacterial symbiont 'Candidatus Endobugula sertula' of the bryozoan Bugula neritina. Appl. Environ. Microbiol. 67:2001;4531-4537.
9. Evans D.A., et al. Synthesis of bryostatin-2. J. Am. Chem. Soc. 121:1999;7540-7552.
10. Ohmori K. Total synthesis of bryostatin-3. Angew. Chem. Int. Ed. Engl. 39:2000;2290-2294.
11. Kageyama M., et al. Synthesis of bryostatin-7. J. Am. Chem. Soc. 112:1990;7407-7408.
12. Meijer L., et al. Inhibition of cyclin-dependent kinases, GSK-3β and CK1 by hymenialdisine, a marine sponge constitutent. Chem. Biol. 7:2000;51-63.
13. Tasdemir D., et al. Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1). J. Med. Chem. 45:2002;529-532.
14. Breton J., Chabot-Fletcher M.C. The natural product hymenialdisine inhibits interleukin-8 production in U937 cells by inhibition of nuclear factor-κB. J. Pharmacol. Exp. Ther. 282:1997;459-466.
15. 2 formation by the marine natural product hymenialdisine. J. Pharmacol. Exp. Ther. 283:1997;955-961.
16. Stevenson C.S., et al. Scytonemin - a marine natural product inhibitor of kinases key in hyperproliferative inflammatory disease. Inflamm. Res. 51:2002;112-114.
17. Stevenson C.S., et al. The identification and characterization of the marine natural product scytonemin as a novel antiproliferative pharmacophore. J. Pharmacol. Exp. Ther. 303:2002;858-866.
18. Kreuter M.H., et al. Inhibition of intrinsic protein tyrosine kinase activity of EGF-receptor kinase complex from human breast cancer cells by the marine sponge metabolite (+)-aeroplysinin-1. Comp. Biochem. Physiol. B. 97:1990;151-158.
19. Hinterding K., et al. Synthesis and biological evaluation of aeroplysinin analogues: a new class of receptor tyrosine kinase inhibitors. Bioorg. Med. Chem. 6:1998;1153-1162.
20. Rodriguez-Nieto S., et al. Antiangiogenic activity of aeroplysinin-1, a brominated compound isolated from a marine sponge. FASEB J. 16:2002;261-263.
21. Lee R.H., et al. Marine sponge polyketide inhibitors of protein tyrosine kinase. Biochem. Biophys. Res. Commun. 184:1992;765-772.
22. v-src protein tyrosine kinase activity. Biochem. Biophys. Res. Commun. 184:1994;260-264.
23. Wessels M., et al. A new tyrosine kinase inhibitor from the marine brown alga Stypopodium zonale. J. Nat. Prod. 62:1999;927-930.
24. Osterhage C., et al. Ascosalipyrrolidinone A, an antimicrobial alkaloid, from the obligate marine fungus Ascochyta salicorniae. J. Org. Chem. 65:2000;6412-6417.
25. 2. Annu. Rev. Pharmacol. Toxicol. 39:1999;175-189.
26. Toqui L., Alaoui-El-Azher M. Mammalian secreted phospholipase A2 and their pathophysiological significance in inflammatory diseases. Curr. Mol. Med. 1:2001;739-754.
27. Soriente A., et al. Manoalide. Curr. Med. Chem. 6:1999;415-431.
28. 2 with antiinflammatroy activity. J. Pharmacol. Exp. Ther. 282:1997;123-131.
29. 2. Br. J. Pharmacol. 126:1999;301-311.
30. 2 inhibitors from the New Caledonian marine sponge Petrosaspongia nigra. J. Nat. Prod. 61:1998;571-575.
31. 2 inhibitor, on acute and chronic inflammation. J. Pharmacol. Exp. Ther. 289:1999;166-172.
32. 2 and other leukocyte functions. J. Nat. Prod. 64:2001;612-615.
33. 2 inhibitors from marine organisms. J. Nat. Prod. 55:1992;1701-1717.
34. Lifeng H., et al. Novel molecules that interact with microtubules and have functional activity similar to Taxol™ Drug Discov. Today. 6:2001;1153-1164.
35. Poncet J. The dolastatins, a family of promising antineoplastic agents. Curr. Pharm. Des. 5:1999;139-162.
36. Luesch H., et al. The cyanobacterial origin of potent anticancer agents originally isolated from sea hares. Curr. Med. Chem. 9:2002;1791-1806.
37. Bai R.L., et al. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J. Biol. Chem. 266:1991;15882-15889.
38. Mooberry S.L., et al. Laulimalide and isolaulimalide, new paclitaxel-like microtubule-s tabilizing agents. Cancer Res. 59:1999;653-660.
39. Hood K.A., et al. The novel cytotoxic sponge metabolite peloruside A, structurally similar to bryostatin-1, has unique bioactivity independent of protein kinase C. Anticancer Drug Des. 16:2001;155-166.
40. Gamble W.R., et al. Cytotoxic and tubulin-interactive hemiasterlins from #Auletta# and Siphonochalina spp. sponges. Bioorg. Med. Chem. 7:1999;1611-1615.
41. Edler M.C., et al. Inhibition of tubulin polymerisation by vitilevuamide, a bicyclic marine peptide, at a site distinct from colchicine, the vinca alkaloids, and dolastatin-10. Biochem. Pharmacol. 63:2002;707-715.
42. Kowalski R.J., et al. The microtubule-stabilzing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits growth of paclitaxel-resitant cell lines. Mol. Pharmacol. 52:1997;613-622.
43. Anthoney D.A., Twelves C.J. DNA: still a target worth aiming at? A Review of new DNA-interactive agents. Am. J. Pharmacogenomics. 1:2001;67-81.
44. Rinehart K.L. Antitumor compounds from tunicates. Med. Res. Rev. 20:2000;1-27.
45. Burres N.S., et al. Antitumor activity and nucleic acid binding properties of dercitin, a new acridine alkaloid isolated from marine Dercitus species sponge. Cancer Res. 49:1989;5267-5274.
46. Burres N.S., et al. Antitumor activity and biochemical effects of topsentin. Biochem. Pharmacol. 42:1991;745-751.
47. Corey E.J., et al. Enantioselective total synthesis of ecteinascidin 743. J. Am. Chem. Soc. 118:1996;9202.
48. Cuevas C., et al. Synthesis of ecteinascidin ET-743 and phthalascidin PT-650 from cyanosafracin B. Org. Lett. 2:2000;2545-2548.
49. Martinez E.J., et al. Antitumor activity- and gene expression-based profiling of ecteinascidin Et 743 and phthalascidin Pt 650. Chem. Biol. 8:2001;1151-1160.
50. Aune G.J., et al. Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action. Anticancer Drugs. 13:2002;545-555.
51. Minuzzo M., et al. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc. Natl. Acad. Sci. U. S. A. 97:2000;6780-6784.
52. Friedman D., et al. Ecteinascidin-743 inhibits activated but not constitutive transcription. Cancer Res. 15:2002;3377-3381.
53. Kanzaki A., et al. Overcoming multidrug resistance P-glycoprotein/MDR1-overexpressing cell lines by ecteinascidin 743. Mol. Cancer Ther. 1:2002;1327-1334.
54. Li W.W., et al. Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent. Clin. Cancer Res. 7:2001;2908-2911.
55. Takebayashi Y., et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide excision repair. Nat. Med. 7:2001;961-966.
56. Damia G., et al. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA repair pathways. Int. J. Cancer. 92:2001;583-588.
57. Takahashi N., et al. Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin. Cancer Res. 7:2001;3251-3257.
58. Verschraegen C.F., Glover K. ET-743 (PharmaMar/NCI/Ortho Biotech). Curr. Opin. Investig. Drugs. 2:2001;1631-1638.
59. Garcia-Fernandez L.F., et al. Aplidin™ induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase Cδ Oncogene. 21:2002;7533-7544.
60. Cuadrado A., et al. Aplidin™ induces apoptosis in human cancer cells via glutathione depletion and sustained activation of the epidermal growth factor receptor, Src, JNK, and p38 MAPK. J. Biol. Chem. 278:2003;241-250.
61. Hamann M.T., et al. Kahalalides: bioactive peptides from a marine mollusk Elysia rufescens and its algal diet Bryopsis sp. J. Org. Chem. 61:1996;6594-6600.
62. Kobayashi E., et al. KRN7000, a novel immunomodulator, and its antitumor activities. Oncol. Res. 7:1995;529-534.
63. Chen Q., et al. The angiostatic sterol squalamine is a calmodulin chaperone. Clin. Cancer Res. 5:(Suppl.):1999;3768S-3797S.
64. Burgoyne D., et al. Contignasterol, a highly oxygenated steroid with the unnatural 14.beta. configuration from the marine sponge Petrosia contignata Thiele, 1899. J. Org. Chem. 57:1992;525-528.
65. Rudi A., et al. Amino acid derivatives from the marine sponge Jaspis digonoxea. J. Nat. Prod. 57:1994;829-832.
66. Tulp M., Bohlin L. Functional versus chemical diversity: is biodiversity important for drug discovery? Trends Pharmacol. Sci. 23:2002;225-231.
67. Cragg G.M., Newman D.J. Chemical diversity: a function of biodiversity. Trends Pharmacol. Sci. 23:2002;404-405.
68. Tulp M., Bohlin L. Chemical diversity: independent of functional diversity. Trends Pharmacol. Sci. 23:2002;405.
69. Reynolds T. A natural edge: nature still offers the greatest drug diversity. J. Natl. Cancer Inst. 91:1999;1608-1610.
70. Rayl A.J.S. Oceans: medicine chests of the future? The Scientist. 13:1999;1.